Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 2/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.48 |
| ▸ | FASN | P49327 | 11/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4199345 | 0.89 | FASN (0.59) | FASN | |
| SCHEMBL4191319 | 0.88 | FASN (0.46) | HDAC4HDAC6FASNUSP30 | |
| SCHEMBL4782771 | 0.88 | FASN (0.48) | FASN | |
| SCHEMBL4194532 | 0.86 | FASN (0.47) | FASN | |
| SCHEMBL4209401 | 0.82 | FASN (0.58) | FASN | |
| SCHEMBL4200218 | 0.82 | FASN (0.52) | FASNEPHX2 | |
| SCHEMBL4196832 | 0.81 | P2RY14 (0.47) | FASNPROKR1P2RY14 | |
| SCHEMBL4196754 | 0.80 | FASN (0.61) | FASN | |
| SCHEMBL14162122 | 0.78 | MEN1 (0.43) | HDAC4HDAC6FASNUSP30 | |
| SCHEMBL4189321 | 0.78 | FASN (0.65) | FASN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | ASTRAZENECA AB (SE) | 2009-05-07 | — | — | US | disclosed |
| WO-2008075064-A1 | PIPERIDINE DERIVATIVES FOR THE TREATMENT OF OBESITY | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118332-A1 | Therapeutic Agents - 551 | GPR119, FABP4, FASN | HDAC4 886/4885HDAC6 339/4885FASN 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.